This is just the start here and it seems to appear the marketing of genomic testing and labs is beginning to resemble the CT scanner rage of a few years ago, except this process is a bit more complicated and still needs more education from the medical side of the business before successful marketing will reach an effective consumer level. BD
PGxPredict tests are a new kind of pharmacogenetic test that uses genetic markers to help doctors make more targeted treatment choices. They can predict a patient’s response to a specific drug, or detect genetic alterations before they lead to disease. And they’re bringing about healthier patients, better utilization, and a more efficient healthcare system.
Two PGxPredict Tests are already available:
PGxPredict™:RITUXIMAB determines whether a patient with follicular non-Hodgkin’s lymphoma is more likely to respond to rituximab.
PGxPredict™:WARFARIN is indicated for patients who are prescribed the anticoagulant warfarin. It detects genetic variants in two genes that are associated with metabolism of warfarin and with sensitivity to warfarin’s effect.
Other Genetic Tests from PGxHealth:
FAMILION® tests detect genetic variants that can cause cardiac channelopathies, rare conditions that can cause irregular heart rhythms and associated heart disorders, including Familial Long QT Syndrome, Brugada Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia and others. The FAMILION HCM test detects mutations that can cause Hypertrophic Cardiomyopathy which is a potentially lethal heart condition.